Brandes Investment Partners LP Decreases Stock Position in Takeda Pharmaceutical Co. $TAK

Brandes Investment Partners LP reduced its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,881,882 shares of the company’s stock after selling 49,921 shares during the period. Brandes Investment Partners LP’s holdings in Takeda Pharmaceutical were worth $60,519,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Private Trust Co. NA raised its holdings in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares during the last quarter. Harbour Investments Inc. raised its holdings in Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock worth $72,000 after acquiring an additional 3,460 shares during the last quarter. Manchester Capital Management LLC raised its holdings in Takeda Pharmaceutical by 91.4% in the 4th quarter. Manchester Capital Management LLC now owns 4,649 shares of the company’s stock worth $72,000 after acquiring an additional 2,220 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $74,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TAK shares. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Wednesday, April 29th. Wall Street Zen lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Trading Down 0.3%

NYSE:TAK opened at $15.70 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.70 and a debt-to-equity ratio of 0.56. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a market cap of $49.95 billion, a PE ratio of 40.24 and a beta of -0.07. The company has a 50 day simple moving average of $16.88 and a two-hundred day simple moving average of $16.68.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. The business had revenue of $6.90 billion during the quarter. Research analysts forecast that Takeda Pharmaceutical Co. will post 1.56 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.